Cargando…

Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role

Endocrine therapy (ET) is a pivotal strategy to manage early- and advanced-stage estrogen receptor-positive (ER+) breast cancer. In patients with metastatic breast cancer (MBC), progression of disease inevitably occurs due to the presence of acquired or intrinsic resistance mechanisms. ET resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lloyd, Maxwell R., Wander, Seth A., Hamilton, Erika, Razavi, Pedram, Bardia, Aditya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340905/ https://www.ncbi.nlm.nih.gov/pubmed/35923930 http://dx.doi.org/10.1177/17588359221113694

Ejemplares similares

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021)

Estrogen receptor degradation: a CUE for endocrine resistance?
por: Musgrove, Elizabeth A
Publicado: (2011)

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
por: D’Souza, Anishka, et al.
Publicado: (2018)

Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer
por: Grinshpun, Albert
Publicado: (2023)

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
por: Bidard, Francois-Clement, et al.
Publicado: (2022)

Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series
por: Brett, Jamie O, et al.
Publicado: (2022)

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer
por: Wang, Yubo, et al.
Publicado: (2023)

Estrogen Receptors as Molecular Targets of Endocrine Therapy for Glioblastoma
por: González-Mora, Andrea Magali, et al.
Publicado: (2021)

Biomarker Genes for Detecting Estrogenic Activity of Endocrine Disruptors via Estrogen Receptors
por: Jung, Eui-Man, et al.
Publicado: (2012)

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology
por: Vidula, Neelima, et al.
Publicado: (2017)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022)

Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2020)

Toxicological Mechanism of Endocrine Disrupting Chemicals:Is Estrogen Receptor Involved?
por: Jeung, Eui-Bae, et al.
Publicado: (2010)

Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability
por: Jeffreys, Sarah A., et al.
Publicado: (2020)

Role of estrogen receptor coregulators in endocrine resistant breast cancer
por: Altwegg, Kristin A., et al.
Publicado: (2021)

Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer
por: Mao, XiaoDan, et al.
Publicado: (2019)

RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer
por: Porta, Camillo
Publicado: (2014)

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER(+) Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
por: Lawson, Mandy, et al.
Publicado: (2023)

SAT-341 Pharmacology and Metabolism of GLL398 an Oral Selective Estrogen Receptor Degrader for Endocrine Therapy of Breast Cancer
por: Guo, Shanchun, et al.
Publicado: (2019)

Estrogen Receptor Mutations and Changes in Estrogen Receptor and Progesterone Receptor Protein Expression in Metastatic or Recurrent Breast Cancer
por: Umekita, Yoshihisa, et al.
Publicado: (1998)

Molecular Basis for Endocrine Disruption by Pesticides Targeting Aromatase and Estrogen Receptor
por: Zhang, Chao, et al.
Publicado: (2020)

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer
por: Hagio, Kanako, et al.
Publicado: (2021)

Thyroid Hormone and Estrogen Promote Endocrine Resistance, Proliferation, Dedifferentiation, and Cancer Stem Cells in Steroid Receptor-Positive Breast Cancers
por: Wahdan-Alaswad, Reema S, et al.
Publicado: (2021)

Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer
por: Yamashita, Hiroko, et al.
Publicado: (2005)

Extracellular Alkaline pH Leads to Increased Metastatic Potential of Estrogen Receptor Silenced Endocrine Resistant Breast Cancer Cells
por: Khajah, Maitham A., et al.
Publicado: (2013)

FOXA1 is a critical determinant of Estrogen Receptor function and endocrine response
por: Hurtado, Antoni, et al.
Publicado: (2010)

Assessment and Molecular Actions of Endocrine-Disrupting Chemicals That Interfere with Estrogen Receptor Pathways
por: Kerdivel, Gwenneg, et al.
Publicado: (2013)

microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
por: Howard, Erin W., et al.
Publicado: (2018)

Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor–Positive Early Breast Cancer
por: Cheung, Yee-Ming, et al.
Publicado: (2019)

Assessment of Five Pesticides as Endocrine-Disrupting Chemicals: Effects on Estrogen Receptors and Aromatase
por: Gea, Marta, et al.
Publicado: (2022)

Corrigendum: Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2023)

Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers
por: Chimento, Adele, et al.
Publicado: (2022)

Placental expression of estrogen receptor beta and its hormone binding variant – comparison with estrogen receptor alpha and a role for estrogen receptors in asymmetric division and differentiation of estrogen-dependent cells
por: Bukovsky, Antonin, et al.
Publicado: (2003)

Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor–Positive Breast Cancer
por: Sarma, Maithreyi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_28ebdp45rfcklrcmcpccv01646